Importantly, this metabolic phenotype was independent of molecular subtype, supporting the view that blocking cholesterol biosynthesis (He et al, 2021), possibly via the upregulated enzymes DHCR7 or DHCR24, could be a promising therapeutic strategy for high-grade serous ovarian cancer. This evidence concerns the gene DHCR24 and ovarian serous adenocarcinoma.